# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-17-008910
Filing Date
2017-05-12
Accepted
2017-05-12 15:26:36
Documents
5
Period of Report
2017-06-15
Effectiveness Date
2017-05-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | dffn20170510_def14a.htm | DEF 14A | 1257415
2 |  | proxy2.jpg | GRAPHIC | 136192
3 |  | proxy1b.jpg | GRAPHIC | 146594
4 |  | proxy1a.jpg | GRAPHIC | 183196
5 |  | dffn20170427_pre14aimg001.jpg | GRAPHIC | 10370
| Complete submission text file | 0001437749-17-008910.txt |  | 1915241

Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37942 | Film No.: 17838228
SIC: 2834 Pharmaceutical Preparations